| Myeloid cells in glioblastoma microenvironment A De Leo, A Ugolini, F Veglia Cells 10 (1), 18, 2020 | 124 | 2020 |
| Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer A Ugolini, VA Tyurin, YY Tyurina, EN Tcyganov, L Donthireddy, VE Kagan, ... JCI insight 5 (15), 2020 | 100 | 2020 |
| Soluble immune checkpoints, gut metabolites and performance status as parameters of response to nivolumab treatment in NSCLC patients IG Zizzari, A Di Filippo, F Scirocchi, FR Di Pietro, H Rahimi, A Ugolini, ... Journal of Personalized Medicine 10 (4), 208, 2020 | 32 | 2020 |
| Immunohistochemical characterization of immune infiltrate in tumor microenvironment of glioblastoma H Rahimi Koshkaki, S Minasi, A Ugolini, G Trevisi, C Napoletano, ... Journal of personalized medicine 10 (3), 112, 2020 | 32 | 2020 |
| CD137+ T-Cells: Protagonists of the Immunotherapy Revolution A Ugolini, M Nuti Cancers 13 (3), 456, 2021 | 29 | 2021 |
| Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer IG Zizzari, A Di Filippo, A Botticelli, L Strigari, A Pernazza, E Rullo, ... Clinical Cancer Research 28 (5), 1027-1037, 2022 | 24 | 2022 |
| IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137+ T-cells A Ugolini, IG Zizzari, F Ceccarelli, A Botticelli, T Colasanti, L Strigari, ... EBioMedicine 62, 2020 | 17 | 2020 |
| Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma A De Leo, A Ugolini, X Yu, F Scirocchi, D Scocozza, B Peixoto, A Pace, ... Immunity 57 (5), 1105-1123. e8, 2024 | 16 | 2024 |
| Rheumatoid factor: a novel determiner in cancer history A Ugolini, M Nuti Cancers 13 (4), 591, 2021 | 13 | 2021 |
| Polymorphonuclear myeloid-derived suppressor cells limit antigen crosspresentation by dendritic cells in cancer. JCI Insight. 2020 A Ugolini, V Tyurin, Y Tyurina, E Tsyganov, L Donthireddy, VE Kagan | 6 | |
| Immunomodulatory effects of tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC) patients. M Nuti, I Zizzari, C Napoletano, A Botticelli, F Calabro, A Gelibter, ... Journal of Clinical Oncology 35 (15_suppl), e14506-e14506, 2017 | 5 | 2017 |
| 4P IgM-rheumatoid factor as a novel biomarker for a reduced survival in anti-PD-1 treated NSCLC patients through the decrease of CD137+ T-cells A Ugolini, IG Zizzari, F Ceccarelli, A Botticelli, T Colasanti, L Strigari, ... Annals of Oncology 31, S1418, 2020 | 3 | 2020 |
| Myeloid activation clears ascites and reveals IL27-dependent regression of metastatic ovarian cancer B Murphy, T Miyamoto, BS Manning, G Mirji, A Ugolini, T Kannan, ... Journal of Experimental Medicine 221 (12), 2024 | | 2024 |
| Intraperitoneal activation of myeloid cells clears ascites and reveals IL27-dependent regression of metastatic ovarian cancer B Murphy, T Miyamoto, BS Manning, G Mirji, A Ugolini, T Kannan, ... bioRxiv, 2024 | | 2024 |
| Probing neutrophils heterogeneity in Glioblastoma: how the metabolism shapes the function of immunosuppressive CD71+ Neutrophils A Ugolini Università degli Studi di Roma" La Sapienza", 2023 | | 2023 |
| DNA response and repair gene mutations as a signature for pembrolizumab response in never-smoker non-small lung cancer: real word approach and patient similarity network analysis M Filetti, M Occhipinti, A Cirillo, F Scirocchi, A Ugolini, R Giusti, ... | | 2023 |
| 1081P DNA damage response and repair (DDR) gene mutations as an alternative mechanism to generate high TMB in never smoker NSCLC patients M Filetti, M Occhipinti, A Cirillo, F Scirocchi, A Ugolini, M Petti, R Giusti, ... Annals of Oncology 33, S1047, 2022 | | 2022 |
| Rheumatoid Factor: A Novel Determiner in Cancer History. Cancers 2021, 13, 591 A Ugolini, M Nuti s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | | 2021 |
| Myeloid Cells in Glioblastoma Microenvironment. Cells 2021, 10, 18 A De Leo, A Ugolini, F Veglia s Note: MDPI stays neu-tral with regard to jurisdictional claims in …, 2020 | | 2020 |
